The estimated Net Worth of John A Scarlett is at least $4.58 Milión dollars as of 4 June 2024. John Scarlett owns over 600,000 units of Geron stock worth over $2,634,000 and over the last 13 years he sold GERN stock worth over $0. In addition, he makes $1,941,140 as Chairman of the Board, President a Chief Executive Officer at Geron.
John has made over 3 trades of the Geron stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 600,000 units of GERN stock worth $1,524,000 on 4 June 2024.
The largest trade he's ever made was exercising 1,340,000 units of Geron stock on 8 February 2023 worth over $2,010,000. On average, John trades about 60,303 units every 124 days since 2012. As of 4 June 2024 he still owns at least 600,000 units of Geron stock.
You can see the complete history of John Scarlett stock trades at the bottom of the page.
Dr. John A. Scarlett M.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. Dr. Scarlett has served as our Chairman of the Board since December 2018, our Chief Executive Officer and a director since joining Geron in September 2011, and President since January 2012. Dr. Scarlett also serves as a member of the boards of directors for Chiasma, Inc., a biopharmaceutical company focused on transforming injectable drugs into oral medications, since February 2015, and CytomX Therapeutics, Inc., an oncology-oriented company, since June 2016. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately-held, oncology-oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., an oncology-oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008, Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology-oriented biopharmaceutical company, and also as its President from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation, a privately-held company focused on endocrine disorders. In 1995, he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly-owned subsidiary of Novo Nordisk A/S, a global pharmaceutical company. Dr. Scarlett received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine.
As the Chairman of the Board, President a Chief Executive Officer of Geron, the total compensation of John Scarlett at Geron is $1,941,140. There are no executives at Geron getting paid more.
John Scarlett is 69, he's been the Chairman of the Board, President a Chief Executive Officer of Geron since 2018. There are 5 older and 15 younger executives at Geron. The oldest executive at Geron Corp. is Stephen N. Rosenfield, 71, who is the Exec. VP, Chief Legal Officer & Corp. Sec..
John's mailing address filed with the SEC is C/O GERON CORPORATION, 919 E. HILLSDALE BLVD, SUITE 250, FOSTER CITY, CA, 94404.
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury a Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Geron executives and other stock owners filed with the SEC include: